Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 11, 2025 · Filed Nov 13, 2025
Balchem's SVP Chief Supply Chain Officer sold $185K of Balchem shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$185,328
Shares × reported transaction price
21 days after results of Oct 21, 2025, 101 days before results of Feb 20, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.8% | −1.9% | +1.1% |
| 30 days | +1.3% | +1.3% | −0.1% |
| 90 days | +13.2% | +1.4% | +11.8% |
| 180 days | +2.5% | +10.5% | −8.0% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
A board member of Balchem sold $923K of Balchem shares. Nobody planned it ahead of time.